NEWS
AT ASCO ’22, PERTHERA ANNOUNCES THE IMMEDIATE AVAILABILITY OF THE PERTHERA AI ANALYTICS PLATFORM TO CANCER CENTERS FOR IMPROVED ANALYTICS, CRITICAL TRIAL OPTIMIZATION AND PATIENT CARE MANAGEMENT
For the first time, Perthera AI’s proven data mining, analytics, optimization and care management platform is now available as an analytics solution for cancer centers to utilize with their own patient data, at no cost. A research study by Cedars Sinai, PanCAN and Perthera’s GIPOCS program was one of the first to utilize data from Perthera’s Analytics solution and was presented at ASCO ‘22.
Comprehensive Analysis Of KRAS Variants In Patients (Pts) With Pancreatic Cancer
Molecular profiling in pancreatic adenocarcinoma (PDAC) has gained traction and we recently demonstrated that targeting actionable alterations can improve patient (pt) outcomes using the Perthera Platform’s real-world evidence database
ACCRU, A Cancer Research Network Operating Within The Mayo Clinic, Has Officially Partnered With Perthera
A leading precision oncology company, to bring innovative clinical trials to cancer patients throughout the country in the Target Panc Program. Perthera, with its Oncology Operating System™, will serve as the centralized “Molecular CRO” under the umbrella protocol.
Perthera and Theralink Technologies Announce Partnership to Allow for Unique Access to Phosphoproteomic Profiling and Drug Target Activation Testing
The new partnership will give oncologists who use Perthera access to the world’s only phosphoprotein panel LDT that directly measures the activation state of targets of over 100 precision therapeutics at once. Perthera will serve as Theralink’s CRO to help bring in and enroll oncology practices in Theralink’s TRACE program, as well as provide treatment matching services to Theralink’s oncology partners.
Perthera and Fight Colorectal Cancer Announce Partnership to Deliver Precision Oncology to Patients with Cancer
The collaborative effort will deliver molecular profiling, personalized treatment recommendations, and clinical trial matching to patients with colorectal cancer.
GenomeWeb – Perthera’s Molecular Tumor Board Improves Patient Outcomes and Overcomes Barriers
GenomeWeb interviews Perthera CEO Gary Gregory and CMO Mike Pishvaian about the Perthera Platform’s proven results, the capabilities of Perthera’s molecular tumor board, and how precision medicine is changing the landscape of cancer care today.
Perthera and PanCAN Publish Pivotal Paper in Lancet Oncology Highlighting the Importance of Selecting Treatments Based on Tumor Mutations
This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients. Patients who receive precision medicine live an average of one year longer than those who do not.
Perthera and Lazarex Cancer Foundation Announce Partnership to Advance Precision Oncology Initiatives
Perthera and Lazarex are matching and enrolling patients in clinical trials through Lazarex’s IMPACT and CARE programs, by utilizing Perthera’s treatment-matching Artificial Intelligence (AI) technology to advance precision medicine for cancer patients.
How Perthera is Using AI and Molecular Data to Bring Precision Medicine to Oncology
Perthera CEO Gary Gregory talks with DocWire News to explain how Perthera’s Precision Oncology Platform is transforming precision medicine in healthcare today, with proven results and advanced technology.
Perthera, UVA, and EVMS team to study the Implementation and Clinical Impact of A Next Generation Precision Oncology Platform for Pancreatic Cancer Patients
Perthera, University of Virginia Health System (UVA) and Eastern Virginia Medical School (EVMS) Awarded $500,000 by Virginia Catalyst Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
Multi-omic molecular comparison of primary versus metastatic pancreatic tumours.
Molecular tumor profiling, which enables physicians to match patients to targeted therapies, is on the rise. Read the latest report published in the British Journal of Cancer.
ASCO 2019 Poster Presentation shows improved overall survival for advanced pancreatic cancer patients enrolled in the Know Your Tumor program.
Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.
Perthera, Inc. Announces the Appointment of Gary L. Gregory as Chief Executive Officer, President and Board Member.
Mr. Gregory is an experienced CEO and Board Member with 30 years of progressively challenging responsibilities in the MedTech Sector. His experience spans numerous companies and positions, including Executive Officer roles across several successful start-up companies, and leadership roles in Fortune 250 companies.
ASCO Daily News: Genomic and Transcriptomic Profiling Finds Potential Predictors and Therapeutic Targets in Pancreatic Cancer
Dr. Mike Pishvaian discusses results from Perthera and PanCAN’s Know Your Tumor study, presented as Abstract 191 at ASCO GI 2019 in San Francisco, CA.
Perthera and the Pancreatic Cancer Action Network Publish Landmark Precision Medicine Study
Using real-world data from over 640 patients with pancreatic cancer, this landmark study demonstrated a 2.2 fold increase in progression-free survival for those being treated with a molecularly-matched therapy. Attached is a pdf of the press release.